NeuroSense Therapeutics Ltd. Warrant (NRSNW)
$0.05
$0.00
(9.65%)
As on 02-Sep-2026 15:55EDT
Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
5 Years Aggregate
CFO
$-18.68 Mln
EBITDA
$-38.95 Mln
Net Profit
$-29.03 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
NeuroSense Therapeutics Ltd. Warrant (NRSNW)
| -84.4 | -49.7 | -73.7 | -91.2 | -35.7 | -- | -- |
|
BSE Sensex*
| -10.7 | -3.7 | 1.8 | -6.4 | 4.5 | 5.3 | 10.1 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
NeuroSense Therapeutics Ltd. Warrant (NRSNW)
| -27.3 | 455.5 | -51.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout NeuroSense Therapeutics Ltd. Warrant (NRSNW)
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is... PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel. Read more
-
Chief Financial Officer
Mr. Or Eisenberg
-
Chief Financial Officer
Mr. Or Eisenberg
-
Headquarters
Herzliya
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for NeuroSense Therapeutics Ltd. Warrant (NRSNW)
What is the current share price of NeuroSense Therapeutics Ltd Warrant (NRSNW) Today?
The share price of NeuroSense Therapeutics Ltd Warrant (NRSNW) is $0.05 (NASDAQ) as of 02-Sep-2026 15:55 EDT. NeuroSense Therapeutics Ltd Warrant (NRSNW) has given a return of -35.75% in the last 3 years.
What is the current PB & PE ratio of NeuroSense Therapeutics Ltd Warrant (NRSNW)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.73 |
-5.24 |
2024 |
-1.00 |
3.96 |
2023 |
-0.12 |
-0.68 |
2022 |
-0.15 |
0.34 |
2021 |
-2.47 |
1.11 |
What is the 52 Week High and Low of NeuroSense Therapeutics Ltd Warrant (NRSNW)?
The 52-week high and low of NeuroSense Therapeutics Ltd Warrant (NRSNW) are Rs 0.70 and Rs 0.04 as of 09-Sep-2026.
What is the market cap of NeuroSense Therapeutics Ltd Warrant (NRSNW)?
NeuroSense Therapeutics Ltd Warrant (NRSNW) has a market capitalisation of -- as on 02-Sep-2026. As per SEBI classification, it is a company.
Should I invest in NeuroSense Therapeutics Ltd Warrant (NRSNW)?
Before investing in NeuroSense Therapeutics Ltd Warrant (NRSNW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.